*Leukopenia and neutropenia *Thrombocytopenia *Anemia *Anorexia *Nausea and vomiting *Hepatotoxicity: this manifests as: Hepatic veno-occlusive disease The major concern that has inhibited the use of<unk>  has been veno-occlusive disease (VOD) and its histological precursor nodular regenerative hyperplasia (NRH). The incidence of NRH with<unk>  was reported as between 33 and 76%. The risk of ensuing VOD is serious and frequently irreversible so this side effect has been a major concern. However, recent evidence using an animal model for<unk> -induced NRH/VOD has shown that, contrary to previous assumptions, NRH/VOD is dose dependent and the mechanism for this has been demonstrated. This has been confirmed in human trials, where<unk>  has proven to be safe but efficacious for coeliac disease when used at doses below those commonly prescribed. This has led to a revival of interest in<unk>  because of its higher efficacy and faster action compared to other thiopurines and immunosuppressants such as mycophenylate.
Tioguanine
Apricitabine
Chlorambucil
Mercaptopurine
Decitabine
Rufinamide
GemOx
Daunorubicin